AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Therapeutic and Diagnostic Pearls in Pediatric Dermatology

Description

In this presentation on pediatric dermatology, the speaker discusses three prominent conditions: atopic dermatitis, molluscum contagiosum, and infantile hemangiomas, while emphasizing therapeutic and diagnostic pearls. Atopic dermatitis is highlighted as a common concern among pediatric patients, addressing typical parental questions regarding the condition's fluctuating nature, its potential to be outgrown, and the safe use of topical treatments. The speaker advocates for shared decision making, stressing the importance of understanding both parental and patient preferences. They discuss the limited FDA-approved topical medications and the significance of off-label use, encouraging communication about treatment options. For molluscum, they mention a newly approved treatment and suggest the use of topical agents and natural therapies like zinc to support immune response. The speaker also introduces topical timolol for infantile hemangiomas, noting its efficacy over corticosteroids and the need for a combined approach to prevent complications. Overall, the talk underscores the importance of tailored care, addressing individual concerns, and building trust with families in managing pediatric dermatologic conditions.

View more

Conclusions

  • Eighty percent of children with atopic dermatitis are expected to outgrow it by adolescence.
  • Topical treatments for atopic dermatitis may be off-label, and clinicians should know the approved indications for use in children.
  • A shared decision-making approach between parents and healthcare providers is crucial for effective management of pediatric skin conditions.
  • Mometasone and mupirocin are effective treatments when used together for managing atopic dermatitis and preventing infections.
  • Parents often perceive a connection between food allergies and eczema; addressing eczema effectively can calm concerns about allergies.
  • Safety concerns regarding the use of topical medications in children can be addressed, as the risk of adrenal suppression is low with proper use.
  • Natural treatments, such as honey and oils, can be complementary options for managing mild to moderate dermatitis.
  • FDA-approved treatments for molluscum contagiosum exist, and options like cantharidin offer effective management.
  • Combining topical timolol with low potency corticosteroids is recommended for treating infantile hemangiomas.
  • Overall, flexibility in treatment options is essential, as dermatology often requires tailoring approaches to each patient's needs.
  • Freeze ME, Balogh EA, Cline A, Feldman SR, Fleischer AB Jr. Comparing prescribing patterns for topical corticosteroids based on their FDA indication by age. Pediatr Dermatol. 2021 Jan;38(1):115-118. doi: 10.1111/pde.14442. Epub 2020 Nov 10. PMID: 33170543.
  • Davallow Ghajar L, Wood Heickman LK, Conaway M, Rogol AD. Low Risk of Adrenal Insufficiency After Use of Low- to Moderate-Potency Topical Corticosteroids for Children With Atopic Dermatitis. Clin Pediatr (Phila). 2019 Apr;58(4):406-412. doi: 10.1177/0009922818825154. Epub 2019 Jan 29. PMID: 30694073.
  • Thompson MM, Hanifin JM. Effective therapy of childhood atopic dermatitis allays food allergy concerns. J Am Acad Dermatol. 2005 Aug;53(2 Suppl 2):S214-9. doi: 10.1016/j.jaad.2005.04.065. PMID: 16021177.
  • Horev A, Sher M, Weissmann S, Golan L. Medihoney Derma Cream Treatment for Mild to Moderate Atopic Dermatitis in Children: An Open-Label Randomized Pilot Study. Dermatitis. 2022 Nov-Dec 01;33(6S):S147-S149. doi: 10.1097/DER.0000000000000913. Epub 2022 Jun 15. PMID: 35703145; PMCID: PMC9674442.
  • Krowchuk DP, Frieden IJ, Mancini AJ, Darrow DH, Blei F, Greene AK, Annam A, Baker CN, Frommelt PC, Hodak A, Pate BM, Pelletier JL, Sandrock D, Weinberg ST, Whelan MA; SUBCOMMITTEE ON THE MANAGEMENT OF INFANTILE HEMANGIOMAS. Clinical Practice Guideline for the Management of Infantile Hemangiomas. Pediatrics. 2019 Jan;143(1):e20183475. doi: 10.1542/peds.2018-3475. PMID: 30584062.
  • Ariwibowo R, Sunardi R, Budiyanto A. Topical Timolol Maleate 0.5% for Infantile Hemangioma: Its Effectiveness Compared to Ultrapotent Topical Corticosteroids - A Single-Center Experience of 278 Cases. Dermatology. 2016;232:566-571. doi: 10.1159/000448396.